Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine Beads-in-Capsule Bioequivalence Study
NCT04452838Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fesoterodine in neurogenic detrusor overactivity (NDO) (6 cohorts), sponsored by Pfizer. Primary endpoints: Area Under the Curve to Infinity of 5-HMT, Area Under the Curve to Last Quantifiable Concentration of 5-HMT and 1 more. Started Jun 2020; status: completed.
02
Drugs
fesoterodine
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT04452838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04452838.